Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2024 | $16.00 → $2.00 | Buy → Neutral | B. Riley Securities |
| 5/14/2024 | $25.00 | Overweight | Stephens |
| 9/6/2023 | $11.60 | Buy | HSBC Securities |
| 2/21/2023 | Outperform → Mkt Perform | William Blair | |
| 9/8/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 8/25/2022 | $16.00 | Buy | B. Riley Securities |
| 8/3/2021 | $57.00 → $45.00 | Buy | HC Wainwright & Co. |
Collaboration With Columbia University Aims To Broaden Access To Cellular Therapies And Inform Gene Therapy Conditioning Study
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors- Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy- Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
3 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously
Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00
HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
DEF 14A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm - In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients - Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 - Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover - Iomab-B was
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approachesSIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significanceIomab-B was well tolerated in the older, heavily pretreated relapsed/refractory AML patients with active disease enrolled in the SIERRA trialActinium to seek strategic partner for Iomab-B for further development in the U.S. following completion of interactions with FDA for additional head-to-head clinical trial to demonstrate overall survival benefitNEW YORK, Sept.
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development